Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells

Apoptosis

Volumn 16, Issue 9, 2011, Pages 959-966

  Arends, J E ^a   Hoepelman, A I M ^a   Nanlohy, N M ^a   Hoppener F J P ^b   Hirsch, K R ^c   Park, J G ^d   Van Baarle, D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Kendle International BV   (Netherlands)

^c GILEAD SCIENCES   (United States)

^d LG Chemical Ltd   (South Korea)

Author keywords

Apoptosis; Caspase 3; Caspase 8; CD95; Hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; FAS ANTIGEN; GS 9450; PLACEBO; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ENZYME ACTIVATION; FATIGUE; FEMALE; FLANK PAIN; FOLLOW UP; GASTROENTERITIS; HEART PALPITATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; MALE; NAUSEA; PAROSMIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHINITIS; SOMNOLENCE; SORE THROAT; VOMITING;

ADULT; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL MARKERS; CASPASE 3; CASPASE 8; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

ANIMALIA; HEPATITIS C VIRUS;

EID: 80052464851     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-011-0620-2     Document Type: Article

References (21)

1. GM Lauer BD Walker 2001 Hepatitis C virus infection N Engl J Med 345 41 52 11439948 10.1056/NEJM200107053450107 1:STN:280:DC%2BD3MzosFGrug%3D%3D (Pubitemid 32634271)
2. DC Rockey DM Bissell 2006 Noninvasive measures of liver fibrosis Hepatology 43 S113 S120 16447288 10.1002/hep.21046 1:CAS:528: DC%2BD28XhvVSktLg%3D
3. RS Hotchkiss A Strasser JE McDunn PE Swanson 2009 Cell death N Engl J Med 361 1570 1583 19828534 10.1056/NEJMra0901217 1:CAS:528:DC%2BD1MXht1OrurzP
4. H Malhi GJ Gores 2008 Cellular and molecular mechanisms of liver injury Gastroenterology 134 1641 1654 18471544 10.1053/j.gastro.2008.03.002 1:CAS:528:DC%2BD1cXntF2gs70%3D (Pubitemid 351615416)
5. K Schulze-Osthoff D Ferrari M Los S Wesselborg ME Peter 1998 Apoptosis signaling by death receptors Eur J Biochem 254 439 459 9688254 10.1046/j.1432-1327.1998.2540439.x 1:CAS:528:DyaK1cXktlertrw%3D (Pubitemid 28308094)
6. N Hayashi E Mita 1999 Involvement of Fas system-mediated apoptosis in pathogenesis of viral hepatitis J Viral Hepat 6 357 365 10607251 10.1046/j.1365-2893.1999.00175.x 1:STN:280:DC%2BD3c%2FnsFahuw%3D%3D (Pubitemid 29470165)
7. K Iken L Huang H Bekele EV Schmidt MJ Koziel 2006 Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction Virology 346 363 372 16336987 10.1016/j.virol.2005.11.017 1:CAS:528:DC%2BD28Xit1CisL0%3D (Pubitemid 43357879)
8. R Fischer T Baumert HE Blum 2007 Hepatitis C virus infection and apoptosis World J Gastroenterol 13 4865 4872 17828818 1:CAS:528: DC%2BD2sXht1yitL%2FN (Pubitemid 47496752)
9. H Bantel K Schulze-Osthoff 2003 Apoptosis in hepatitis C virus infection Cell Death Differ 10 Suppl 1 S48 S58 12655346 10.1038/sj.cdd.4401119 1:CAS:528:DC%2BD3sXltFGrsL0%3D (Pubitemid 36511852)
10. ME Guicciardi GJ Gores 2005 Apoptosis: a mechanism of acute and chronic liver injury Gut 54 1024 1033 15951554 10.1136/gut.2004.053850 1:CAS:528:DC%2BD2MXmsFKqtrY%3D (Pubitemid 40873921)
11. J Kountouras C Zavos D Chatzopoulos 2003 Apoptosis in hepatitis C J Viral Hepat 10 335 342 12969183 10.1046/j.1365-2893.2003.00452.x 1:STN:280: DC%2BD3svivFGhuw%3D%3D (Pubitemid 37159417)
12. F Calabrese P Pontisso E Pettenazzo L Benvegnu A Vario L Chemello A Alberti M Valente 2000 Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels Hepatology 31 1153 1159 10796892 10.1053/he.2000.7123 1:CAS:528: DC%2BD3cXjtlylurs%3D (Pubitemid 30233241)
13. S Pianko S Patella G Ostapowicz P Desmond W Sievert 2001 Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection J Viral Hepat 8 406 413 11703571 10.1046/j.1365-2893.2001.00316.x 1:STN:280:DC%2BD3Mnlt1KltA%3D%3D (Pubitemid 35013565)
14. A Piekarska R Kubiak A Omulecka W Szymczak J Piekarski 2007 Expression of tumour necrosis factor-related apoptosis-inducing ligand and caspase-3 in relation to grade of inflammation and stage of fibrosis in chronic hepatitis C Histopathology 51 597 604 17927580 10.1111/j.1365-2559.2007.02863.x 1:STN:280:DC%2BD2sngsFaiug%3D%3D (Pubitemid 47572881)
15. H Bantel A Lugering C Poremba N Lugering J Held W Domschke K Schulze-Osthoff 2001 Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection Hepatology 34 758 767 11584373 10.1053/jhep.2001.28229 1:CAS:528:DC%2BD3MXns1Kisrk%3D (Pubitemid 32928001)
16. Höppener F, Kim JA, Park MJ, Choi HJ (2010) Safety, tolerability, and pharmacokinetics of GS-9450 in healthy male and female volunteers. In: 44th Annual meeting of the European association for the study of the liver category 5f
17. Manns MP, Lawitz E, Hoepelman IM, Choi HJ, Lee YJ, Cornpropst M, Liang W, King B, Hirsch KR, Oldach D, Rousseau FS (2010) Short term safety, tolerability, pharmacokinetics and preliminary activity of GS-9450, a selective caspase inhibitor, in patients with chronic HCV infection. In: 45th Annual meeting of the European association for the study of the liver. Abstr. no. 15
18. ML Shiffman P Pockros JG McHutchison ER Schiff M Morris G Burgess 2010 Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor-a randomized placebo-controlled study in patients with chronic hepatitis C Aliment Pharmacol Ther 31 969 978 20163376 1:CAS:528: DC%2BC3cXmtFOgs7c%3D
19. PJ Pockros ER Schiff ML Shiffman JG McHutchison RG Gish NH Afdhal M Makhviladze M Huyghe D Hecht T Oltersdorf DA Shapiro 2007 Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C Hepatology 46 324 329 17654603 10.1002/hep.21664 1:CAS:528:DC%2BD2sXhtVSisb7J (Pubitemid 47344766)
20. E Toubi A Kessel L Goldstein G Slobodin E Sabo Z Shmuel E Zuckerman 2001 Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity J Hepatol 35 774 780 11738105 10.1016/S0168-8278(01)00207-0 1:STN:280:DC%2BD3Mnpt1SltA%3D%3D (Pubitemid 34717669)
21. C Soguero M Joo KA Chianese-Bullock DT Nguyen K Tung YS Hahn 2002 Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model J Virol 76 9345 9354 12186917 10.1128/JVI.76.18.9345- 9354.2002 1:CAS:528:DC%2BD38XmslCjtLw%3D (Pubitemid 34919892)